Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women

P. L. Selby, Munro Peacock

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The effect of the plasma oestradiol concentration on climacteric symptoms, gonadotrophin release, and bone resorption was studied in three groups of postmenopausal women given 0.025 mg, 0.05 mg, or 0.1 mg transdermal oestradiol daily. There was a dose related reduction in symptoms, plasma follicle stimulating hormone concentration, and urinary calcium and hydroxyproline excretion. The relation of the response to plasma oestradiol values was similar for each variable with an initial large reduction and little change in response to increases in the plasma oestradiol concentration above 150 pmol/l (41 pg/ml). Hormone replacement therapy producing an effect equivalent to higher oestradiol concentrations is likely in increase the risk of side effects without conferring any additional benefit.

Original languageEnglish (US)
Pages (from-to)1337-1339
Number of pages3
JournalBMJ (Clinical research ed.)
Volume293
Issue number6558
StatePublished - 1986
Externally publishedYes

Fingerprint

Estradiol
Estrogens
Bone and Bones
Hydroxyproline
Hormone Replacement Therapy
Follicle Stimulating Hormone
Bone Resorption
Gonadotropins
Calcium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women. / Selby, P. L.; Peacock, Munro.

In: BMJ (Clinical research ed.), Vol. 293, No. 6558, 1986, p. 1337-1339.

Research output: Contribution to journalArticle

@article{7a2ce4f0e5c04d56b0c0f8b11e4c4105,
title = "Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women",
abstract = "The effect of the plasma oestradiol concentration on climacteric symptoms, gonadotrophin release, and bone resorption was studied in three groups of postmenopausal women given 0.025 mg, 0.05 mg, or 0.1 mg transdermal oestradiol daily. There was a dose related reduction in symptoms, plasma follicle stimulating hormone concentration, and urinary calcium and hydroxyproline excretion. The relation of the response to plasma oestradiol values was similar for each variable with an initial large reduction and little change in response to increases in the plasma oestradiol concentration above 150 pmol/l (41 pg/ml). Hormone replacement therapy producing an effect equivalent to higher oestradiol concentrations is likely in increase the risk of side effects without conferring any additional benefit.",
author = "Selby, {P. L.} and Munro Peacock",
year = "1986",
language = "English (US)",
volume = "293",
pages = "1337--1339",
journal = "British Medical Journal",
issn = "0267-0623",
publisher = "BMJ Publishing Group",
number = "6558",

}

TY - JOUR

T1 - Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women

AU - Selby, P. L.

AU - Peacock, Munro

PY - 1986

Y1 - 1986

N2 - The effect of the plasma oestradiol concentration on climacteric symptoms, gonadotrophin release, and bone resorption was studied in three groups of postmenopausal women given 0.025 mg, 0.05 mg, or 0.1 mg transdermal oestradiol daily. There was a dose related reduction in symptoms, plasma follicle stimulating hormone concentration, and urinary calcium and hydroxyproline excretion. The relation of the response to plasma oestradiol values was similar for each variable with an initial large reduction and little change in response to increases in the plasma oestradiol concentration above 150 pmol/l (41 pg/ml). Hormone replacement therapy producing an effect equivalent to higher oestradiol concentrations is likely in increase the risk of side effects without conferring any additional benefit.

AB - The effect of the plasma oestradiol concentration on climacteric symptoms, gonadotrophin release, and bone resorption was studied in three groups of postmenopausal women given 0.025 mg, 0.05 mg, or 0.1 mg transdermal oestradiol daily. There was a dose related reduction in symptoms, plasma follicle stimulating hormone concentration, and urinary calcium and hydroxyproline excretion. The relation of the response to plasma oestradiol values was similar for each variable with an initial large reduction and little change in response to increases in the plasma oestradiol concentration above 150 pmol/l (41 pg/ml). Hormone replacement therapy producing an effect equivalent to higher oestradiol concentrations is likely in increase the risk of side effects without conferring any additional benefit.

UR - http://www.scopus.com/inward/record.url?scp=0022995784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022995784&partnerID=8YFLogxK

M3 - Article

VL - 293

SP - 1337

EP - 1339

JO - British Medical Journal

JF - British Medical Journal

SN - 0267-0623

IS - 6558

ER -